psoralen

Small moleculeexperimental

Psoralen is the parent compound in a family of naturally occurring organic compounds known as the linear furanocoumarins. It is structurally related to coumarin by the addition of a fused furan ring, and may be considered as a derivative of umbelliferone. Psoralen occurs naturally in the seeds of Psoralea corylifolia, as well as in the common fig, celery, parsley, West Indian satinwood, and in all citrus fruits. It is widely used in PUVA treatment for psoriasis, eczema, vitiligo, and cutaneous T-cell lymphoma; these applications are typically through the use of medications such as Methoxsalen. Many furanocoumarins are extremely toxic to fish, and some are deposited in streams in Indonesia to catch fish. — Wikipedia

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 1999 (NCT00005092)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • DNABINDING AGENT

    DNA binding agent

Chemistry & pharmacology

Loading structure…

SMILES

O=c1ccc2cc3ccoc3cc2o1
Mol. weight
186.17 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • psoralen
  • psoralen

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00724061N/ASep 1, 2008National Cancer Institute (NCI), Northwestern University
NCT00005092Phase 1Mar 1, 1999National Cancer Institute (NCI), University of Texas at Houston
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government2021999
Northwestern UniversityAcademic/Hospital1112008
University of Texas at HoustonAcademic/Hospital1111999
3 organizations
Page 1 / 1